Abstract: Provided are an anti-B7H3 chimeric antigen receptor and an application thereof. The anti-B7H3 chimeric antigen receptor comprises an antigen binding domain, a hinge region, a transmembrane domain and a signaling transfer structural domain. The antigen binding domain is an anti-human B7H3 antibody. The anti-B7H3 chimeric antigen receptor has a specific targeting effect on B7H3-positive tumor cells, T cells that express the anti-B7H3 chimeric antigen receptor have significant killing effects in vitro and in vivo, can effectively remove the B7H3-positive tumor cells, and having important significance in the field of tumor therapy.
Type:
Application
Filed:
December 22, 2020
Publication date:
February 22, 2024
Applicant:
GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD
Inventors:
Guangchao Li, Min Luo, Wen Ding, Zhao Zhou, Xuejun Wang
Abstract: Provided are an anti-Claudin 18.2 antigen-binding fragment or antibody, and the use thereof. CDR3 of a heavy chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 3. CDR3 of a light chain variable region of the antigen-binding fragment comprises an amino acid sequence shown in SEQ ID NO. 6. The provided antigen-binding fragment and anti-Claudin 18.2 antibody can specifically bind to a variety of sources of Claudin 18.2 proteins, have no binding effect on other proteins, and have a high specificity. In addition, a chimeric antigen receptor and a CAR-T cell prepared by means of the antibody have obvious cytotoxicity on cells stably expressing the Claudin 18.2 protein.
Type:
Application
Filed:
December 22, 2020
Publication date:
February 15, 2024
Applicant:
GUANGZHOU BIO-GENE TECHNOLOGY CO., LTD
Inventors:
Min Luo, Guangchao Li, Wen Ding, Zhao Zhou, Xuejun Wang
Abstract: The present disclosure provides use of chemokine receptor CXCR5, wherein CAR-T cells with enhanced chemotaxis are obtained by modifying chimeric antigen receptor T cells (CAR-T cells) utilizing the chemotactic signal between CXCR5 and its ligand CXCL13. The chemokine receptor CXCR5 can guide CAR-T cells to migrate to tumors. It has an excellent ability to enhance the chemotaxis of CAR-T cells, can specifically clear tumor cells, and effectively solve the problem of poor efficacy of the existing CAR-T therapy for solid tumors, thereby exhibiting broad application prospects and great market value.